Clinical trial
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
NCT05195749 is registered in ClinicalTrials.gov with 101 Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
- Lead sponsor
- 101 Therapeutics
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 13, 2022
- Completion date
- February 14, 2023
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.